| 1.75 0 (0%) | 09-25 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.81 | 1-year : | 3.37 |
| Resists | First : | 2.4 | Second : | 2.88 |
| Pivot price | 1.93 |
|||
| Supports | First : | 1.62 | Second : | 1.35 |
| MAs | MA(5) : | 1.74 |
MA(20) : | 2.07 |
| MA(100) : | 4.55 |
MA(250) : | 5.69 |
|
| MACD | MACD : | -0.5  |
Signal : | -0.5 |
| %K %D | K(14,3) : | 14.1 |
D(3) : | 13.1 |
| RSI | RSI(14): 22.9 | |||
| 52-week | High : | 13.19 | Low : | 1.62 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ SILO ] has closed above bottom band by 28.3%. Bollinger Bands are 50.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 18 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.81 - 1.82 | 1.82 - 1.83 |
| Low: | 1.71 - 1.72 | 1.72 - 1.73 |
| Close: | 1.73 - 1.75 | 1.75 - 1.77 |
Silo Pharma Inc. operates as a developmental-stage biopharmaceutical firm dedicated to creating treatments for a variety of underserviced medical conditions. These include stress-related psychiatric disorders, persistent pain syndromes, and diseases impacting the central nervous system (CNS). The company's approach combines both traditional and psychedelic therapies, with a strong emphasis on innovative formulations and advanced drug delivery systems. Leading its pipeline is SPC-15, an intranasal treatment engineered to address post-traumatic stress disorder (PTSD) and anxiety disorders stemming from stress. Another key development is SP-26, a time-release, ketamine-loaded implant designed to provide relief for fibromyalgia and chronic pain. Furthermore, Silo Pharma is advancing two preclinical programs: SPC-14, an intranasal compound targeting Alzheimer's disease, and SPU-16, a CNS-homing peptide intended for the management of multiple sclerosis (MS). The company's research and development efforts frequently involve collaborations with prominent academic institutions such as Columbia University and the University of Maryland, Baltimore. Founded in 2010, the company adopted its current name, Silo Pharma, Inc., in September 2020, having previously operated as Uppercut Brands, Inc. Silo Pharma is headquartered in Sarasota, Florida.
Thu, 24 Sep 2026
Why Is Silo Pharma (NASDAQ:SILO) Moving Into Focus? - Kalkine Media
Fri, 18 Sep 2026
Silo Pharma Receives USPTO Notice of Allowance for SPC-15 Patent Covering Stress-Induced Behavioral Response Prevention - Quiver Quantitative
Fri, 18 Sep 2026
A PTSD treatment moves closer to U.S. patent protection - Stock Titan
Fri, 18 Sep 2026
Silo Pharma Receives U.S. Patent Allowance for SPC-15 PTSD Treatment, Expanding Intellectual Property Portfolio - GlobeNewswire
Wed, 09 Sep 2026
Silo Pharma to Participate in IPAC-RS 2026 Nasal Innovation Forum as It Advances SPC-15 Development - Quiver Quantitative
Wed, 09 Sep 2026
Silo Pharma to Highlight Patented Nose-to-Brain Drug Delivery Technology for PTSD at 2026 Nasal Innovation Forum - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 2 (M) |
| Held by Insiders | 1.57e+006 (%) |
| Held by Institutions | 11.7 (%) |
| Shares Short | 155 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -4.45e+006 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -8 % |
| Return on Assets (ttm) | 250.4 % |
| Return on Equity (ttm) | -44.3 % |
| Qtrly Rev. Growth | 54080 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -121.64 |
| EBITDA (p.s.) | -10653.3 |
| Qtrly Earnings Growth | -3.8 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -3 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.02 |
| Price to Cash Flow | 0.25 |
| Dividend | 0 |
| Forward Dividend | 82950 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|